Braavos

High-Level Overview

Braavos Investment Advisers is a London-based venture capital firm founded in 2019, managing over $500 million in assets under management. Its mission centers on partnering with visionary entrepreneurs to transform cutting-edge scientific research into scalable businesses, with a focus on early-stage investments (seed and Series A) in sectors like biotechnology, artificial intelligence, renewable energy, chemical engineering, energy efficiency, and simulation.[1] The firm's investment philosophy emphasizes scientific rigor, transformative potential, and addressing global challenges through sustainable technologies, typically leading or following rounds with ticket sizes from £500,000 to £10 million and an average of £39 million.[1]

Braavos has a strong track record, including leading a £22 million investment in OXCCU, an Oxfordshire-based biotechnology firm in June 2023, contributing significantly to the startup ecosystem by bridging deep technical innovation with market opportunities in high-growth, regulated environments.[1]

Origin Story

Braavos Investment Advisers was established in 2019 in London as a venture capital firm dedicated to early-stage science and technology investments.[1] Key details on founding partners are not specified in available sources, but the firm's evolution has centered on refining its focus on companies leveraging scientific breakthroughs amid rising demand for sustainable innovations in biotech, AI, and energy sectors.[1] This positioning emerged as global challenges like climate change and technological disruption intensified, allowing Braavos to quickly build a portfolio targeting ventures with clear paths from research to commercialization.[1]

Core Differentiators

• Unique Investment Model: Emphasizes lead and follow investments in early-stage ventures with scientific foundations, prioritizing scalability, long-term impact, and execution in complex environments over traditional metrics.[1]
• Network Strength: London-based with a global outlook, connecting founders to resources for commercializing breakthrough science, particularly in Europe (e.g., UK investments like OXCCU).[1]
• Track Record: Manages $500M+ AUM; notable deals include leading £22M in OXCCU (biotech), demonstrating ability to deploy significant capital in high-potential rounds averaging £39M.[1]
• Operating Support: Advises founders to highlight technical rigor, team expertise, and market bridging, providing guidance on regulatory and scalability hurdles in science-driven fields.[1]

Role in the Broader Tech Landscape

Braavos rides the trend of deep tech commercialization, where scientific advancements in biotech, AI, and clean energy address pressing global issues like sustainability and efficiency.[1] Timing is ideal amid post-2020 surges in climate tech funding and AI applications, with market forces like regulatory tailwinds for renewables and energy transitions favoring its portfolio.[1] The firm influences the ecosystem by de-risking early-stage science ventures, fostering innovation spillovers (e.g., OXCCU's CO2 conversion tech), and setting benchmarks for investor-founder partnerships in transformative sectors.[1]

Quick Take & Future Outlook

Braavos is poised for expanded influence as deep tech scales, with trends like AI-driven simulations and biotech breakthroughs likely amplifying its portfolio returns.[1] Expect larger funds and more cross-sector bets, evolving its role from early backer to ecosystem shaper amid tightening energy regulations and sustainability mandates. This positions Braavos to sustain its mission of turning research into real-world impact, much like its strategic push into critical industries from day one.[1]